Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
| Autor: | Robert N. Weinreb, Baldo Scassellati Sforzolini, Jason L Vittitow, Makoto Araie |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Asian Continental Ancestry Group
Adult Male medicine.medical_specialty Intraocular pressure genetic structures Prostaglandin Ocular hypertension Glaucoma Sitting Dinoprost Tonometry Tonometry Ocular Asian People Double-Blind Method Japan Ocular Normal tension glaucoma Internal medicine Medicine Humans Pharmacology (medical) Adverse effect General Clinical Medicine Antihypertensive Agents Original Research Medicine(all) Diurnal business.industry Prostaglandins F Synthetic Nitric oxide Pharmacology and Pharmaceutical Sciences General Medicine medicine.disease Rheumatology eye diseases Latanoprostene Bunod Nocturnal Open-Angle Anesthesia Prostaglandins F Synthetic sense organs Ophthalmic Solutions business Glaucoma Open-Angle |
| Zdroj: | Advances in Therapy Araie, M; Sforzolini, BS; Vittitow, J; & Weinreb, RN. (2015). Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects. Advances in Therapy, 32(11), 1128-1139. doi: 10.1007/s12325-015-0260-y. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/5gq5x8gc Advances in therapy, vol 32, iss 11 |
| ISSN: | 1865-8652 0741-238X |
| Popis: | Introduction Latanoprostene bunod is a novel nitric oxide (NO)-donating prostaglandin F2α receptor agonist in clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. We evaluated the effect of latanoprostene bunod 0.024% instilled once daily (QD) on lowering IOP over a 24-h period in healthy Japanese subjects following 14 days of treatment. Methods This was a single-arm, single-center, open-label clinical study of 24 healthy Japanese male volunteers. A baseline IOP profile was established in both eyes in the sitting position at 8 PM, 10 PM, 12 AM, 2 AM, 4 AM, 8 AM, 10 AM, 12 PM, and 4 PM using a Goldmann applanation tonometer. Subjects subsequently instilled latanoprostene bunod 0.024% QD at 8 PM for 14 days in both eyes. The absolute and change from baseline in sitting IOP was assessed on day 14. Results The mean (SD) age of the subjects was 26.8 (6.3) years, and mean (SD) baseline IOP was 13.6 (1.3) mmHg in the study eye. Latanoprostene bunod 0.024% instilled QD for 14 days reduced IOP at all the evaluated time points (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink